Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790290 | 0.87 | MAPT (0.41) | KDM4EPKML3MBTL1GAAALDH1A1 | |
| SCHEMBL6790298 | 0.78 | GRIA1 (0.42) | KDM4EGAAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL6780170 | 0.78 | GRIA1 (0.42) | KDM4EGAAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14287201 | 0.75 | ALDH1A1 (0.40) | KDM4EPKMALDH1A1MAPTMAPK1 | |
| SCHEMBL6785386 | 0.74 | MAPT (0.39) | KDM4EPKML3MBTL1GAAALDH1A1 | |
| SCHEMBL6780461 | 0.74 | MAPT (0.45) | KDM4EPKMALDH1A1MAPTMAPK1 | |
| SCHEMBL6784833 | 0.72 | MAPT (0.41) | KDM4EPKMGAAALDH1A1HPGD | |
| SCHEMBL6612610 | 0.70 | ALDH1A1 (0.40) | KDM4EPKML3MBTL1GAAALDH1A1 | |
| SCHEMBL6783364 | 0.70 | BAZ2B (0.41) | KDM4EGAAALDH1A1HPGDMAPT | |
| SCHEMBL7983678 | 0.70 | BAZ2B (0.41) | KDM4EGAAALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| US-6703391-B2 | THROMBOSIS, BRAIN DISORDERS, CARDIOVASCULAR DISORDERS, ALZHEIMER'S DISEASE, HUNTINGTON DISEASES | NEUROSEARCH A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | disclosed |
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | CHRNA3, CHRNA7, CHRNB3 | KDM4E 3236/4885PKM 4478/4885L3MBTL1 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.